Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
AntidiabeticsSUBCUTANEOUSGeneric

RYZODEG 70/30

INSULIN ASPART; INSULIN DEGLUDEC

Standard Dose
90 UNITS/3ML;210 UNITS/3ML (30 UNITS/ML;70 UNITS/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview RYZODEG 70/30 is listed in Drugs@FDA under application 203313 (BLA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient INSULIN ASPART; INSULIN DEGLUDEC Form and strength SOLUTION;SUBCUTANEOUS - 90 UNITS/3ML;210 UNITS/3ML (30 UNITS/ML;70 UNITS/ML) Sponsor NOVO Submission history Latest submission status date: 2022-10-06 00:00:00.

Structured Monograph

Clinical summary

Approval overview RYZODEG 70/30 is listed in Drugs@FDA under application 203313 (BLA). Review priority: STANDARD Marketing status: Discontinued Active ingredient INSULIN ASPART; INSULIN DEGLUDEC Form and strength SOLUTION;SUBCUTANEOUS - 90 UNITS/3ML;210 UNITS/3ML (30 UNITS/ML;70 UNITS/ML) Sponsor NOVO Submission history Latest submission status date: 2022-10-06 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
RYZODEG 70/30 (INSULIN ASPART; INSULIN DEGLUDEC) | Drug Monograph | MedicHelpline